Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by WORKINMONTANAon Jan 08, 2019 10:14am

47 Views

Post# 29199789

RE:RE:RE:Salzman didn't have anything to do with the selling

It was the last six trades for just over 90,000 shares total from seller 007 to buyer 007 seconds before close. I bet the online statements for the sellers account have been since updated this morning already.

Jack4000 wrote:
Was that the end of day 823 shares at nine and a half?

WORKINMONTANA wrote: Whoever the seller was from 007 TD at 4:00pm yesterday should check their online statements for the amount of shares covered in the sale. I’ve caught my institution trading shares I didn’t even own during my trade transaction. They awarded me lowest trade commission price for ever after speaking with a supervisor.

The trade went seller 007 to buyer 007.... looks fishy